Skip to main content

Haas Jason

In the past year, 1 open-market purchase filing worth $20.0K and 2 sale filings worth $3.74M.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
$20.0K
1 filing
Sold
$3.74M
2 filings
Net
−$3.72M
Bought minus sold
Companies
2
With open-market trades

Trades

Every Form 4 that lists Haas Jason as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

LGND Ligand Pharmaceuticals Inc

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 14, 2026 (view filing)5:04 PM ETAug 122 daysHaas JasonDirectorSSale−7.14K$292.81−$2.09M−64.2%3.98K after
Jun 15, 2026 (view filing)Jun 123 daysHaas JasonDirectorSSale−6.46K$255.58−$1.65M−56.5%4.98K after2 lots

ODTX Odyssey Therapeutics, Inc.

Chief Financial Officer1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 11, 2026 (view filing)May 83 daysHaas JasonChief Financial OfficerPPurchase+1.00K$20.00+$20.0K+1.6%62.9K after

SYRS Syros Pharmaceuticals, Inc.

Chief Financial Officer2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 20, 2024 (view filing)5:00 PM ETNov 182 daysHaas JasonChief Financial OfficerSSale−137.8K$0.2103−$29.0K−100.0%0 after
Sep 12, 2024 (view filing)Sep 10-122 daysHaas JasonChief Financial OfficerPPurchase+100.0K$1.61+$161.5K+407.3%124.6K after3 lots